TORONTO and HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the voting results from the Company’s annual meeting of shareholders held today, September 25, 2025 (the “Meeting”). Medicenna is pleased to announce that all nominees listed in the management information circular dated August 13, 2025 (the “Circular”), were elected as di ...

GeoVax Labs (NasdaqCM:GOVX) 2025 Conference September 25, 2025 03:55 PM ET Company ParticipantsDavid Dodd - Chairman, President & CEONoneWelcome back. We have an update from GeoVax Labs. Trades on the NASDAQ under GeoVax. It's a clinical-stage biotech company developing novel vaccines for many of the world's most threatening infectious diseases and therapies for solid tumor cancers. So happy to welcome back Chairman, President, and CEO David A. Dodd. David, welcome back.David DoddThank you, Anna. Today what ...

Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpointStatistically significant maintenance of function (p<0.0001)Company will request pre-BLA meeting with FDA to discuss submission pathway CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the ...

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. KBR was aware that the Department of Defense had ongoing concerns about its HomeSafe joint venture, specifically about its ability to fulfill its obligations related to the relocation of armed forces services members and their families. Despite knowing about these concerns, the Company claimed to investors that its performance would continue to grow. Based on these facts, KBR's public statements were fa ...

Accessibility StatementSkip Navigation Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Quanex Building Products Corporation ("Quanex " or "the Company") (NYSE: NX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t ...

Accessibility StatementSkip Navigation LOS ANGELES, Sept. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible l ...

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the first participants have been dosed in its Phase 3 ...

Jay Olson from Oppenheimer sets a price target of $30 for Immuneering Corporation (NASDAQ:IMRX), indicating a significant potential upside.Immuneering announces an underwritten public offering of 18.96 million shares, aiming to raise approximately $175 million.The company's stock shows volatility, with a current decrease of 13.33%, amidst its efforts to strengthen its financial position through strategic financial activities.On September 25, 2025, Jay Olson from Oppenheimer set a price target of $30 for Imm ...

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).Results were presented at the International ATTR Amyloidosis Annual Meeting for Patients and Doctors. The results were simultaneously published in the New England Journal of Medicine.DataDeep, durable and consistent TTR reductions continue to be observed. Across ...

Key Takeaways BDTX's silevertinib targets 50 EGFR mutations, including C797S resistance seen after Tagrisso. Enrollment completed in frontline cohort; initial silevertinib data expected in Q4 2025. BDTX seeks FDA feedback in 2026 and potential partnerships for pivotal silevertinib studies.Black Diamond Therapeutics’ (BDTX) lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting epidermal gro ...